BACKGROUND: Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features. PROCEDURE: Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0-M5. All children were entered on the Children's Cancer Group therapeutic research study CCG 2891. RESULTS: The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AML FAB M6 (19 children), or AML FAB M7 (53 children) were similar. Children with AML FAB M7 were diagnosed at a significantly younger age (P = 0.001). Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P < 0.001), and an increased frequency of -7/7q- (P = 0.003) at presentation. All three groups had significantly inferior overall survival (OS) (P < 0.001) and event free survival (P < 0.001) compared with the 748 children diagnosed with AML FAB M0-M5 when assessed from entry on study. This poor survival was largely attributable to induction death and failure. However, when assessed from successful completion of induction therapy, the 5-year OS (P = 0.090)(49.1 vs. 56.9%) and disease-free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML. CONCLUSIONS: Childhood AML FAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes.
BACKGROUND:Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features. PROCEDURE: Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0-M5. All children were entered on the Children's Cancer Group therapeutic research study CCG 2891. RESULTS: The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AMLFAB M6 (19 children), or AMLFAB M7 (53 children) were similar. Children with AMLFAB M7 were diagnosed at a significantly younger age (P = 0.001). Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P < 0.001), and an increased frequency of -7/7q- (P = 0.003) at presentation. All three groups had significantly inferior overall survival (OS) (P < 0.001) and event free survival (P < 0.001) compared with the 748 children diagnosed with AMLFAB M0-M5 when assessed from entry on study. This poor survival was largely attributable to induction death and failure. However, when assessed from successful completion of induction therapy, the 5-year OS (P = 0.090)(49.1 vs. 56.9%) and disease-free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML. CONCLUSIONS: Childhood AMLFAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes.
Authors: April D Sorrell; Todd A Alonzo; Joanne M Hilden; Robert B Gerbing; Thomas W Loew; Lois Hathaway; Dorothy Barnard; Jeffrey W Taub; Yaddanapudi Ravindranath; Franklin O Smith; Robert J Arceci; William G Woods; Alan S Gamis Journal: Cancer Date: 2012-03-05 Impact factor: 6.860
Authors: Patrick K Campbell; Yang Zong; Shengping Yang; Sheng Zhou; Jeffrey E Rubnitz; Brian P Sorrentino Journal: Leuk Res Date: 2011-10 Impact factor: 3.156
Authors: Tanja A Gruber; Amanda Larson Gedman; Jinghui Zhang; Cary S Koss; Suresh Marada; Huy Q Ta; Shann-Ching Chen; Xiaoping Su; Stacey K Ogden; Jinjun Dang; Gang Wu; Vedant Gupta; Anna K Andersson; Stanley Pounds; Lei Shi; John Easton; Michael I Barbato; Heather L Mulder; Jayanthi Manne; Jianmin Wang; Michael Rusch; Swati Ranade; Ramapriya Ganti; Matthew Parker; Jing Ma; Ina Radtke; Li Ding; Giovanni Cazzaniga; Andrea Biondi; Steven M Kornblau; Farhad Ravandi; Hagop Kantarjian; Stephen D Nimer; Konstanze Döhner; Hartmut Döhner; Timothy J Ley; Paola Ballerini; Sheila Shurtleff; Daisuke Tomizawa; Souichi Adachi; Yasuhide Hayashi; Akio Tawa; Lee-Yung Shih; Der-Cherng Liang; Jeffrey E Rubnitz; Ching-Hon Pui; Elaine R Mardis; Richard K Wilson; James R Downing Journal: Cancer Cell Date: 2012-11-13 Impact factor: 31.743
Authors: Hiroto Inaba; Yinmei Zhou; Oussama Abla; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Eveline de Bont; Tai-Tsung Chang; Ursula Creutzig; Michael Dworzak; Sarah Elitzur; Alcira Fynn; Erik Forestier; Henrik Hasle; Der-Cherng Liang; Vincent Lee; Franco Locatelli; Riccardo Masetti; Barbara De Moerloose; Dirk Reinhardt; Laura Rodriguez; Nadine Van Roy; Shuhong Shen; Takashi Taga; Daisuke Tomizawa; Allen E J Yeoh; Martin Zimmermann; Susana C Raimondi Journal: Blood Date: 2015-07-27 Impact factor: 22.113